nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—Diphemanil Methylsulfate—Tamoxifen—breast cancer	0.179	0.212	CrCrCtD
Mepenzolate—Loperamide—Toremifene—breast cancer	0.103	0.122	CrCrCtD
Mepenzolate—Dextropropoxyphene—Toremifene—breast cancer	0.0843	0.0998	CrCrCtD
Mepenzolate—Levomethadyl Acetate—Tamoxifen—breast cancer	0.0645	0.0764	CrCrCtD
Mepenzolate—Loperamide—Tamoxifen—breast cancer	0.0645	0.0764	CrCrCtD
Mepenzolate—Methadyl Acetate—Tamoxifen—breast cancer	0.0645	0.0764	CrCrCtD
Mepenzolate—Clofedanol—Toremifene—breast cancer	0.0609	0.0722	CrCrCtD
Mepenzolate—Benzyl Benzoate—Toremifene—breast cancer	0.0547	0.0647	CrCrCtD
Mepenzolate—Dextropropoxyphene—Tamoxifen—breast cancer	0.0529	0.0627	CrCrCtD
Mepenzolate—Methadone—Tamoxifen—breast cancer	0.0443	0.0525	CrCrCtD
Mepenzolate—Clofedanol—Tamoxifen—breast cancer	0.0383	0.0453	CrCrCtD
Mepenzolate—Benzyl Benzoate—Tamoxifen—breast cancer	0.0343	0.0407	CrCrCtD
Mepenzolate—Fexofenadine—SLCO1B1—breast cancer	0.000711	0.165	CrCbGaD
Mepenzolate—Aclidinium—BCHE—breast cancer	0.000593	0.138	CrCbGaD
Mepenzolate—Dizziness—Ixabepilone—breast cancer	0.000447	0.00376	CcSEcCtD
Mepenzolate—Hypersensitivity—Idarubicin—breast cancer	0.000445	0.00375	CcSEcCtD
Mepenzolate—Dry mouth—Tamoxifen—breast cancer	0.000445	0.00374	CcSEcCtD
Mepenzolate—Abdominal distension—Paclitaxel—breast cancer	0.000444	0.00373	CcSEcCtD
Mepenzolate—Vomiting—Ixabepilone—breast cancer	0.00043	0.00362	CcSEcCtD
Mepenzolate—Tension—Thiotepa—breast cancer	0.000428	0.0036	CcSEcCtD
Mepenzolate—Anaphylactic shock—Melphalan—breast cancer	0.000427	0.00359	CcSEcCtD
Mepenzolate—Nausea—Exemestane—breast cancer	0.000426	0.00358	CcSEcCtD
Mepenzolate—Dry mouth—Goserelin—breast cancer	0.000425	0.00357	CcSEcCtD
Mepenzolate—Nervousness—Thiotepa—breast cancer	0.000424	0.00356	CcSEcCtD
Mepenzolate—Headache—Ixabepilone—breast cancer	0.000424	0.00356	CcSEcCtD
Mepenzolate—Dizziness—Anastrozole—breast cancer	0.000421	0.00354	CcSEcCtD
Mepenzolate—Dizziness—Letrozole—breast cancer	0.000421	0.00354	CcSEcCtD
Mepenzolate—Confusional state—Goserelin—breast cancer	0.00042	0.00353	CcSEcCtD
Mepenzolate—Tachycardia—Melphalan—breast cancer	0.000416	0.0035	CcSEcCtD
Mepenzolate—Anaphylactic shock—Goserelin—breast cancer	0.000416	0.0035	CcSEcCtD
Mepenzolate—Vision blurred—Thiotepa—breast cancer	0.000411	0.00346	CcSEcCtD
Mepenzolate—Tachycardia—Goserelin—breast cancer	0.000406	0.00342	CcSEcCtD
Mepenzolate—Vomiting—Anastrozole—breast cancer	0.000405	0.00341	CcSEcCtD
Mepenzolate—Vomiting—Letrozole—breast cancer	0.000405	0.00341	CcSEcCtD
Mepenzolate—Palpitations—Vinorelbine—breast cancer	0.000404	0.0034	CcSEcCtD
Mepenzolate—Feeling abnormal—Chlorambucil—breast cancer	0.000403	0.00339	CcSEcCtD
Mepenzolate—Nausea—Ixabepilone—breast cancer	0.000402	0.00338	CcSEcCtD
Mepenzolate—Dizziness—Raloxifene—breast cancer	0.0004	0.00336	CcSEcCtD
Mepenzolate—Headache—Anastrozole—breast cancer	0.000399	0.00336	CcSEcCtD
Mepenzolate—Headache—Letrozole—breast cancer	0.000399	0.00336	CcSEcCtD
Mepenzolate—Urinary retention—Capecitabine—breast cancer	0.000398	0.00335	CcSEcCtD
Mepenzolate—Insomnia—Tamoxifen—breast cancer	0.000394	0.00332	CcSEcCtD
Mepenzolate—Urticaria—Chlorambucil—breast cancer	0.000389	0.00327	CcSEcCtD
Mepenzolate—Vomiting—Raloxifene—breast cancer	0.000384	0.00323	CcSEcCtD
Mepenzolate—Vomiting—Idarubicin—breast cancer	0.000384	0.00323	CcSEcCtD
Mepenzolate—Constipation—Vinblastine—breast cancer	0.000384	0.00323	CcSEcCtD
Mepenzolate—Headache—Idarubicin—breast cancer	0.000379	0.00318	CcSEcCtD
Mepenzolate—Headache—Raloxifene—breast cancer	0.000379	0.00318	CcSEcCtD
Mepenzolate—Nausea—Anastrozole—breast cancer	0.000378	0.00318	CcSEcCtD
Mepenzolate—Nausea—Letrozole—breast cancer	0.000378	0.00318	CcSEcCtD
Mepenzolate—Insomnia—Goserelin—breast cancer	0.000376	0.00317	CcSEcCtD
Mepenzolate—Anaphylactic shock—Vinorelbine—breast cancer	0.000373	0.00314	CcSEcCtD
Mepenzolate—Constipation—Tamoxifen—breast cancer	0.000373	0.00313	CcSEcCtD
Mepenzolate—Somnolence—Goserelin—breast cancer	0.00037	0.00311	CcSEcCtD
Mepenzolate—Feeling abnormal—Vinblastine—breast cancer	0.00037	0.00311	CcSEcCtD
Mepenzolate—Abdominal distension—Capecitabine—breast cancer	0.000364	0.00306	CcSEcCtD
Mepenzolate—Tachycardia—Vinorelbine—breast cancer	0.000364	0.00306	CcSEcCtD
Mepenzolate—Hypersensitivity—Chlorambucil—breast cancer	0.000361	0.00303	CcSEcCtD
Mepenzolate—Nausea—Idarubicin—breast cancer	0.000359	0.00302	CcSEcCtD
Mepenzolate—Nausea—Raloxifene—breast cancer	0.000359	0.00302	CcSEcCtD
Mepenzolate—Confusional state—Thiotepa—breast cancer	0.000359	0.00302	CcSEcCtD
Mepenzolate—Constipation—Goserelin—breast cancer	0.000356	0.00299	CcSEcCtD
Mepenzolate—Vision blurred—Mitoxantrone—breast cancer	0.000355	0.00299	CcSEcCtD
Mepenzolate—Asthenia—Chlorambucil—breast cancer	0.000351	0.00295	CcSEcCtD
Mepenzolate—Tachycardia—Thiotepa—breast cancer	0.000347	0.00292	CcSEcCtD
Mepenzolate—Urticaria—Tamoxifen—breast cancer	0.000346	0.00291	CcSEcCtD
Mepenzolate—Feeling abnormal—Goserelin—breast cancer	0.000343	0.00289	CcSEcCtD
Mepenzolate—Vision blurred—Fluorouracil—breast cancer	0.00034	0.00286	CcSEcCtD
Mepenzolate—Urticaria—Melphalan—breast cancer	0.000339	0.00285	CcSEcCtD
Mepenzolate—Urticaria—Goserelin—breast cancer	0.000331	0.00278	CcSEcCtD
Mepenzolate—Hypersensitivity—Vinblastine—breast cancer	0.000331	0.00278	CcSEcCtD
Mepenzolate—Asthenia—Vinblastine—breast cancer	0.000322	0.00271	CcSEcCtD
Mepenzolate—Hypersensitivity—Tamoxifen—breast cancer	0.000321	0.0027	CcSEcCtD
Mepenzolate—Constipation—Vinorelbine—breast cancer	0.000319	0.00268	CcSEcCtD
Mepenzolate—Somnolence—Thiotepa—breast cancer	0.000317	0.00266	CcSEcCtD
Mepenzolate—Hypersensitivity—Melphalan—breast cancer	0.000314	0.00264	CcSEcCtD
Mepenzolate—Asthenia—Tamoxifen—breast cancer	0.000313	0.00263	CcSEcCtD
Mepenzolate—Vomiting—Chlorambucil—breast cancer	0.000311	0.00262	CcSEcCtD
Mepenzolate—Confusional state—Mitoxantrone—breast cancer	0.00031	0.00261	CcSEcCtD
Mepenzolate—Confusional state—Irinotecan—breast cancer	0.00031	0.00261	CcSEcCtD
Mepenzolate—Anaphylactic shock—Irinotecan—breast cancer	0.000307	0.00259	CcSEcCtD
Mepenzolate—Anaphylactic shock—Mitoxantrone—breast cancer	0.000307	0.00259	CcSEcCtD
Mepenzolate—Feeling abnormal—Vinorelbine—breast cancer	0.000307	0.00258	CcSEcCtD
Mepenzolate—Hypersensitivity—Goserelin—breast cancer	0.000307	0.00258	CcSEcCtD
Mepenzolate—Asthenia—Melphalan—breast cancer	0.000306	0.00258	CcSEcCtD
Mepenzolate—Constipation—Thiotepa—breast cancer	0.000304	0.00256	CcSEcCtD
Mepenzolate—Tension—Paclitaxel—breast cancer	0.000301	0.00254	CcSEcCtD
Mepenzolate—Tachycardia—Mitoxantrone—breast cancer	0.0003	0.00252	CcSEcCtD
Mepenzolate—Anaphylactic shock—Gemcitabine—breast cancer	0.000299	0.00252	CcSEcCtD
Mepenzolate—Asthenia—Goserelin—breast cancer	0.000299	0.00251	CcSEcCtD
Mepenzolate—Nervousness—Paclitaxel—breast cancer	0.000298	0.00251	CcSEcCtD
Mepenzolate—Confusional state—Fluorouracil—breast cancer	0.000297	0.0025	CcSEcCtD
Mepenzolate—Dizziness—Vinblastine—breast cancer	0.000297	0.0025	CcSEcCtD
Mepenzolate—Urticaria—Vinorelbine—breast cancer	0.000296	0.00249	CcSEcCtD
Mepenzolate—Anaphylactic shock—Fluorouracil—breast cancer	0.000294	0.00248	CcSEcCtD
Mepenzolate—Feeling abnormal—Thiotepa—breast cancer	0.000293	0.00247	CcSEcCtD
Mepenzolate—Nausea—Chlorambucil—breast cancer	0.000291	0.00245	CcSEcCtD
Mepenzolate—Vision blurred—Paclitaxel—breast cancer	0.00029	0.00244	CcSEcCtD
Mepenzolate—Dizziness—Tamoxifen—breast cancer	0.000288	0.00242	CcSEcCtD
Mepenzolate—Tachycardia—Fluorouracil—breast cancer	0.000287	0.00242	CcSEcCtD
Mepenzolate—Vomiting—Vinblastine—breast cancer	0.000285	0.0024	CcSEcCtD
Mepenzolate—Urticaria—Thiotepa—breast cancer	0.000283	0.00238	CcSEcCtD
Mepenzolate—Headache—Vinblastine—breast cancer	0.000281	0.00236	CcSEcCtD
Mepenzolate—Insomnia—Irinotecan—breast cancer	0.000278	0.00234	CcSEcCtD
Mepenzolate—Vomiting—Tamoxifen—breast cancer	0.000277	0.00233	CcSEcCtD
Mepenzolate—Dizziness—Goserelin—breast cancer	0.000275	0.00232	CcSEcCtD
Mepenzolate—Hypersensitivity—Vinorelbine—breast cancer	0.000275	0.00231	CcSEcCtD
Mepenzolate—Somnolence—Mitoxantrone—breast cancer	0.000273	0.0023	CcSEcCtD
Mepenzolate—Somnolence—Irinotecan—breast cancer	0.000273	0.0023	CcSEcCtD
Mepenzolate—Headache—Tamoxifen—breast cancer	0.000273	0.0023	CcSEcCtD
Mepenzolate—Palpitations—Paclitaxel—breast cancer	0.000272	0.00228	CcSEcCtD
Mepenzolate—Vomiting—Melphalan—breast cancer	0.000271	0.00228	CcSEcCtD
Mepenzolate—Insomnia—Gemcitabine—breast cancer	0.000271	0.00228	CcSEcCtD
Mepenzolate—Asthenia—Vinorelbine—breast cancer	0.000267	0.00225	CcSEcCtD
Mepenzolate—Nausea—Vinblastine—breast cancer	0.000266	0.00224	CcSEcCtD
Mepenzolate—Insomnia—Fluorouracil—breast cancer	0.000266	0.00224	CcSEcCtD
Mepenzolate—Somnolence—Gemcitabine—breast cancer	0.000266	0.00224	CcSEcCtD
Mepenzolate—Vomiting—Goserelin—breast cancer	0.000265	0.00223	CcSEcCtD
Mepenzolate—Constipation—Irinotecan—breast cancer	0.000263	0.00221	CcSEcCtD
Mepenzolate—Constipation—Mitoxantrone—breast cancer	0.000263	0.00221	CcSEcCtD
Mepenzolate—Hypersensitivity—Thiotepa—breast cancer	0.000262	0.00221	CcSEcCtD
Mepenzolate—Somnolence—Fluorouracil—breast cancer	0.000262	0.0022	CcSEcCtD
Mepenzolate—Headache—Goserelin—breast cancer	0.000261	0.00219	CcSEcCtD
Mepenzolate—Clemastine—CYP2D6—breast cancer	0.00026	0.0605	CrCbGaD
Mepenzolate—Nausea—Tamoxifen—breast cancer	0.000259	0.00218	CcSEcCtD
Mepenzolate—Constipation—Gemcitabine—breast cancer	0.000256	0.00215	CcSEcCtD
Mepenzolate—Dry mouth—Paclitaxel—breast cancer	0.000256	0.00215	CcSEcCtD
Mepenzolate—Trospium—CYP2D6—breast cancer	0.000255	0.0594	CrCbGaD
Mepenzolate—Asthenia—Thiotepa—breast cancer	0.000255	0.00215	CcSEcCtD
Mepenzolate—Levomethadyl Acetate—CYP19A1—breast cancer	0.000255	0.0592	CrCbGaD
Mepenzolate—Abdominal distension—Epirubicin—breast cancer	0.000254	0.00213	CcSEcCtD
Mepenzolate—Nausea—Melphalan—breast cancer	0.000253	0.00213	CcSEcCtD
Mepenzolate—Feeling abnormal—Mitoxantrone—breast cancer	0.000253	0.00213	CcSEcCtD
Mepenzolate—Feeling abnormal—Irinotecan—breast cancer	0.000253	0.00213	CcSEcCtD
Mepenzolate—Confusional state—Paclitaxel—breast cancer	0.000253	0.00213	CcSEcCtD
Mepenzolate—Anaphylactic shock—Paclitaxel—breast cancer	0.000251	0.00211	CcSEcCtD
Mepenzolate—Erectile dysfunction—Methotrexate—breast cancer	0.000248	0.00209	CcSEcCtD
Mepenzolate—Nausea—Goserelin—breast cancer	0.000247	0.00208	CcSEcCtD
Mepenzolate—Feeling abnormal—Gemcitabine—breast cancer	0.000247	0.00208	CcSEcCtD
Mepenzolate—Dizziness—Vinorelbine—breast cancer	0.000247	0.00207	CcSEcCtD
Mepenzolate—Tachycardia—Paclitaxel—breast cancer	0.000245	0.00206	CcSEcCtD
Mepenzolate—Urticaria—Mitoxantrone—breast cancer	0.000244	0.00205	CcSEcCtD
Mepenzolate—Feeling abnormal—Fluorouracil—breast cancer	0.000243	0.00204	CcSEcCtD
Mepenzolate—Drowsiness—Methotrexate—breast cancer	0.00024	0.00202	CcSEcCtD
Mepenzolate—Vision blurred—Capecitabine—breast cancer	0.000238	0.002	CcSEcCtD
Mepenzolate—Vomiting—Vinorelbine—breast cancer	0.000237	0.00199	CcSEcCtD
Mepenzolate—Dizziness—Thiotepa—breast cancer	0.000235	0.00198	CcSEcCtD
Mepenzolate—Abdominal distension—Doxorubicin—breast cancer	0.000235	0.00198	CcSEcCtD
Mepenzolate—Urticaria—Fluorouracil—breast cancer	0.000234	0.00197	CcSEcCtD
Mepenzolate—Headache—Vinorelbine—breast cancer	0.000234	0.00196	CcSEcCtD
Mepenzolate—Palpitations—Docetaxel—breast cancer	0.00023	0.00194	CcSEcCtD
Mepenzolate—Insomnia—Paclitaxel—breast cancer	0.000227	0.00191	CcSEcCtD
Mepenzolate—Hypersensitivity—Irinotecan—breast cancer	0.000227	0.00191	CcSEcCtD
Mepenzolate—Hypersensitivity—Mitoxantrone—breast cancer	0.000227	0.00191	CcSEcCtD
Mepenzolate—Vomiting—Thiotepa—breast cancer	0.000226	0.0019	CcSEcCtD
Mepenzolate—Drowsiness—Epirubicin—breast cancer	0.000225	0.00189	CcSEcCtD
Mepenzolate—Clemastine—CYP3A4—breast cancer	0.000223	0.0519	CrCbGaD
Mepenzolate—Headache—Thiotepa—breast cancer	0.000223	0.00188	CcSEcCtD
Mepenzolate—Somnolence—Paclitaxel—breast cancer	0.000223	0.00187	CcSEcCtD
Mepenzolate—Palpitations—Capecitabine—breast cancer	0.000223	0.00187	CcSEcCtD
Mepenzolate—Nausea—Vinorelbine—breast cancer	0.000221	0.00186	CcSEcCtD
Mepenzolate—Asthenia—Mitoxantrone—breast cancer	0.000221	0.00186	CcSEcCtD
Mepenzolate—Asthenia—Irinotecan—breast cancer	0.000221	0.00186	CcSEcCtD
Mepenzolate—Hypersensitivity—Fluorouracil—breast cancer	0.000217	0.00182	CcSEcCtD
Mepenzolate—Dry mouth—Docetaxel—breast cancer	0.000217	0.00182	CcSEcCtD
Mepenzolate—Asthenia—Gemcitabine—breast cancer	0.000215	0.00181	CcSEcCtD
Mepenzolate—Constipation—Paclitaxel—breast cancer	0.000214	0.0018	CcSEcCtD
Mepenzolate—Confusional state—Docetaxel—breast cancer	0.000214	0.0018	CcSEcCtD
Mepenzolate—Anaphylactic shock—Docetaxel—breast cancer	0.000213	0.00179	CcSEcCtD
Mepenzolate—Nausea—Thiotepa—breast cancer	0.000211	0.00178	CcSEcCtD
Mepenzolate—Dry mouth—Capecitabine—breast cancer	0.00021	0.00177	CcSEcCtD
Mepenzolate—Drowsiness—Doxorubicin—breast cancer	0.000208	0.00175	CcSEcCtD
Mepenzolate—Confusional state—Capecitabine—breast cancer	0.000207	0.00175	CcSEcCtD
Mepenzolate—Tachycardia—Docetaxel—breast cancer	0.000207	0.00174	CcSEcCtD
Mepenzolate—Feeling abnormal—Paclitaxel—breast cancer	0.000207	0.00174	CcSEcCtD
Mepenzolate—Dizziness—Irinotecan—breast cancer	0.000203	0.00171	CcSEcCtD
Mepenzolate—Tachycardia—Capecitabine—breast cancer	0.000201	0.00169	CcSEcCtD
Mepenzolate—Urticaria—Paclitaxel—breast cancer	0.000199	0.00168	CcSEcCtD
Mepenzolate—Vomiting—Irinotecan—breast cancer	0.000195	0.00164	CcSEcCtD
Mepenzolate—Vomiting—Mitoxantrone—breast cancer	0.000195	0.00164	CcSEcCtD
Mepenzolate—Dizziness—Fluorouracil—breast cancer	0.000195	0.00164	CcSEcCtD
Mepenzolate—Headache—Irinotecan—breast cancer	0.000193	0.00162	CcSEcCtD
Mepenzolate—Headache—Mitoxantrone—breast cancer	0.000193	0.00162	CcSEcCtD
Mepenzolate—Insomnia—Docetaxel—breast cancer	0.000192	0.00162	CcSEcCtD
Mepenzolate—Vomiting—Gemcitabine—breast cancer	0.00019	0.0016	CcSEcCtD
Mepenzolate—Somnolence—Docetaxel—breast cancer	0.000189	0.00159	CcSEcCtD
Mepenzolate—Headache—Gemcitabine—breast cancer	0.000188	0.00158	CcSEcCtD
Mepenzolate—Vomiting—Fluorouracil—breast cancer	0.000187	0.00157	CcSEcCtD
Mepenzolate—Insomnia—Capecitabine—breast cancer	0.000186	0.00157	CcSEcCtD
Mepenzolate—Darifenacin—CYP2D6—breast cancer	0.000185	0.0431	CrCbGaD
Mepenzolate—Hypersensitivity—Paclitaxel—breast cancer	0.000185	0.00155	CcSEcCtD
Mepenzolate—Headache—Fluorouracil—breast cancer	0.000184	0.00155	CcSEcCtD
Mepenzolate—Nausea—Irinotecan—breast cancer	0.000183	0.00154	CcSEcCtD
Mepenzolate—Nausea—Mitoxantrone—breast cancer	0.000183	0.00154	CcSEcCtD
Mepenzolate—Constipation—Docetaxel—breast cancer	0.000182	0.00153	CcSEcCtD
Mepenzolate—Fexofenadine—CYP2D6—breast cancer	0.00018	0.0419	CrCbGaD
Mepenzolate—Asthenia—Paclitaxel—breast cancer	0.00018	0.00151	CcSEcCtD
Mepenzolate—Nausea—Gemcitabine—breast cancer	0.000178	0.0015	CcSEcCtD
Mepenzolate—Vision blurred—Methotrexate—breast cancer	0.000177	0.00149	CcSEcCtD
Mepenzolate—Constipation—Capecitabine—breast cancer	0.000176	0.00148	CcSEcCtD
Mepenzolate—Feeling abnormal—Docetaxel—breast cancer	0.000175	0.00147	CcSEcCtD
Mepenzolate—Nausea—Fluorouracil—breast cancer	0.000175	0.00147	CcSEcCtD
Mepenzolate—Tension—Epirubicin—breast cancer	0.000172	0.00145	CcSEcCtD
Mepenzolate—Nervousness—Epirubicin—breast cancer	0.000171	0.00143	CcSEcCtD
Mepenzolate—Feeling abnormal—Capecitabine—breast cancer	0.00017	0.00143	CcSEcCtD
Mepenzolate—Dizziness—Paclitaxel—breast cancer	0.000166	0.00139	CcSEcCtD
Mepenzolate—Vision blurred—Epirubicin—breast cancer	0.000166	0.00139	CcSEcCtD
Mepenzolate—Benzatropine—CYP2D6—breast cancer	0.000165	0.0383	CrCbGaD
Mepenzolate—Urticaria—Capecitabine—breast cancer	0.000163	0.00137	CcSEcCtD
Mepenzolate—Tension—Doxorubicin—breast cancer	0.000159	0.00134	CcSEcCtD
Mepenzolate—Vomiting—Paclitaxel—breast cancer	0.000159	0.00134	CcSEcCtD
Mepenzolate—Darifenacin—CYP3A4—breast cancer	0.000159	0.037	CrCbGaD
Mepenzolate—Nervousness—Doxorubicin—breast cancer	0.000158	0.00133	CcSEcCtD
Mepenzolate—Headache—Paclitaxel—breast cancer	0.000157	0.00132	CcSEcCtD
Mepenzolate—Hypersensitivity—Docetaxel—breast cancer	0.000157	0.00132	CcSEcCtD
Mepenzolate—Palpitations—Epirubicin—breast cancer	0.000155	0.00131	CcSEcCtD
Mepenzolate—Confusional state—Methotrexate—breast cancer	0.000154	0.0013	CcSEcCtD
Mepenzolate—Anaphylactic shock—Methotrexate—breast cancer	0.000153	0.00129	CcSEcCtD
Mepenzolate—Vision blurred—Doxorubicin—breast cancer	0.000153	0.00129	CcSEcCtD
Mepenzolate—Asthenia—Docetaxel—breast cancer	0.000152	0.00128	CcSEcCtD
Mepenzolate—Hypersensitivity—Capecitabine—breast cancer	0.000152	0.00128	CcSEcCtD
Mepenzolate—Methadone—CYP19A1—breast cancer	0.000149	0.0347	CrCbGaD
Mepenzolate—Nausea—Paclitaxel—breast cancer	0.000149	0.00125	CcSEcCtD
Mepenzolate—Asthenia—Capecitabine—breast cancer	0.000148	0.00124	CcSEcCtD
Mepenzolate—Dry mouth—Epirubicin—breast cancer	0.000146	0.00123	CcSEcCtD
Mepenzolate—Confusional state—Epirubicin—breast cancer	0.000145	0.00122	CcSEcCtD
Mepenzolate—Palpitations—Doxorubicin—breast cancer	0.000144	0.00121	CcSEcCtD
Mepenzolate—Anaphylactic shock—Epirubicin—breast cancer	0.000143	0.00121	CcSEcCtD
Mepenzolate—Dizziness—Docetaxel—breast cancer	0.000141	0.00118	CcSEcCtD
Mepenzolate—Tachycardia—Epirubicin—breast cancer	0.00014	0.00118	CcSEcCtD
Mepenzolate—Insomnia—Methotrexate—breast cancer	0.000139	0.00117	CcSEcCtD
Mepenzolate—Somnolence—Methotrexate—breast cancer	0.000136	0.00115	CcSEcCtD
Mepenzolate—Dizziness—Capecitabine—breast cancer	0.000136	0.00114	CcSEcCtD
Mepenzolate—Dry mouth—Doxorubicin—breast cancer	0.000135	0.00114	CcSEcCtD
Mepenzolate—Vomiting—Docetaxel—breast cancer	0.000135	0.00114	CcSEcCtD
Mepenzolate—Confusional state—Doxorubicin—breast cancer	0.000134	0.00112	CcSEcCtD
Mepenzolate—Headache—Docetaxel—breast cancer	0.000133	0.00112	CcSEcCtD
Mepenzolate—Anaphylactic shock—Doxorubicin—breast cancer	0.000133	0.00112	CcSEcCtD
Mepenzolate—Vomiting—Capecitabine—breast cancer	0.000131	0.0011	CcSEcCtD
Mepenzolate—Insomnia—Epirubicin—breast cancer	0.00013	0.00109	CcSEcCtD
Mepenzolate—Tachycardia—Doxorubicin—breast cancer	0.000129	0.00109	CcSEcCtD
Mepenzolate—Headache—Capecitabine—breast cancer	0.000129	0.00108	CcSEcCtD
Mepenzolate—Fexofenadine—ABCB1—breast cancer	0.000129	0.0299	CrCbGaD
Mepenzolate—Somnolence—Epirubicin—breast cancer	0.000127	0.00107	CcSEcCtD
Mepenzolate—Nausea—Docetaxel—breast cancer	0.000126	0.00106	CcSEcCtD
Mepenzolate—Feeling abnormal—Methotrexate—breast cancer	0.000126	0.00106	CcSEcCtD
Mepenzolate—Constipation—Epirubicin—breast cancer	0.000123	0.00103	CcSEcCtD
Mepenzolate—Nausea—Capecitabine—breast cancer	0.000122	0.00103	CcSEcCtD
Mepenzolate—Urticaria—Methotrexate—breast cancer	0.000122	0.00102	CcSEcCtD
Mepenzolate—Dextropropoxyphene—CYP2D6—breast cancer	0.00012	0.028	CrCbGaD
Mepenzolate—Insomnia—Doxorubicin—breast cancer	0.00012	0.00101	CcSEcCtD
Mepenzolate—Levomethadyl Acetate—CYP3A4—breast cancer	0.00012	0.0278	CrCbGaD
Mepenzolate—Feeling abnormal—Epirubicin—breast cancer	0.000118	0.000994	CcSEcCtD
Mepenzolate—Somnolence—Doxorubicin—breast cancer	0.000118	0.000992	CcSEcCtD
Mepenzolate—Loperamide—CYP2D6—breast cancer	0.000115	0.0267	CrCbGaD
Mepenzolate—Urticaria—Epirubicin—breast cancer	0.000114	0.000958	CcSEcCtD
Mepenzolate—Constipation—Doxorubicin—breast cancer	0.000113	0.000954	CcSEcCtD
Mepenzolate—Hypersensitivity—Methotrexate—breast cancer	0.000113	0.000949	CcSEcCtD
Mepenzolate—Asthenia—Methotrexate—breast cancer	0.00011	0.000924	CcSEcCtD
Mepenzolate—Feeling abnormal—Doxorubicin—breast cancer	0.000109	0.000919	CcSEcCtD
Mepenzolate—Hypersensitivity—Epirubicin—breast cancer	0.000106	0.000888	CcSEcCtD
Mepenzolate—Urticaria—Doxorubicin—breast cancer	0.000105	0.000886	CcSEcCtD
Mepenzolate—Dextropropoxyphene—CYP3A4—breast cancer	0.000103	0.024	CrCbGaD
Mepenzolate—Asthenia—Epirubicin—breast cancer	0.000103	0.000865	CcSEcCtD
Mepenzolate—Fentanyl—CYP3A4—breast cancer	0.000102	0.0238	CrCbGaD
Mepenzolate—Dizziness—Methotrexate—breast cancer	0.000101	0.000852	CcSEcCtD
Mepenzolate—Loperamide—CYP3A4—breast cancer	9.85e-05	0.0229	CrCbGaD
Mepenzolate—Hypersensitivity—Doxorubicin—breast cancer	9.77e-05	0.000822	CcSEcCtD
Mepenzolate—Vomiting—Methotrexate—breast cancer	9.74e-05	0.000819	CcSEcCtD
Mepenzolate—Headache—Methotrexate—breast cancer	9.6e-05	0.000807	CcSEcCtD
Mepenzolate—Asthenia—Doxorubicin—breast cancer	9.52e-05	0.0008	CcSEcCtD
Mepenzolate—Dizziness—Epirubicin—breast cancer	9.48e-05	0.000797	CcSEcCtD
Mepenzolate—Vomiting—Epirubicin—breast cancer	9.11e-05	0.000767	CcSEcCtD
Mepenzolate—Nausea—Methotrexate—breast cancer	9.1e-05	0.000765	CcSEcCtD
Mepenzolate—Headache—Epirubicin—breast cancer	8.98e-05	0.000755	CcSEcCtD
Mepenzolate—Dizziness—Doxorubicin—breast cancer	8.77e-05	0.000738	CcSEcCtD
Mepenzolate—Nausea—Epirubicin—breast cancer	8.52e-05	0.000716	CcSEcCtD
Mepenzolate—Fentanyl—ABCB1—breast cancer	8.51e-05	0.0198	CrCbGaD
Mepenzolate—Vomiting—Doxorubicin—breast cancer	8.43e-05	0.000709	CcSEcCtD
Mepenzolate—Headache—Doxorubicin—breast cancer	8.31e-05	0.000699	CcSEcCtD
Mepenzolate—Loperamide—ABCB1—breast cancer	8.2e-05	0.0191	CrCbGaD
Mepenzolate—Methadone—CYP2D6—breast cancer	8.17e-05	0.019	CrCbGaD
Mepenzolate—Nausea—Doxorubicin—breast cancer	7.88e-05	0.000663	CcSEcCtD
Mepenzolate—Methadone—CYP3A4—breast cancer	7.01e-05	0.0163	CrCbGaD
Mepenzolate—Methadone—ABCB1—breast cancer	5.84e-05	0.0136	CrCbGaD
Mepenzolate—CHRM2—Signaling Pathways—ITPR1—breast cancer	8.18e-06	0.000251	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—MTHFR—breast cancer	8.16e-06	0.00025	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STAT5A—breast cancer	8.13e-06	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ERBB4—breast cancer	8.13e-06	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MMP3—breast cancer	8.13e-06	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CB—breast cancer	8.11e-06	0.000248	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SMAD4—breast cancer	7.97e-06	0.000244	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SMAD4—breast cancer	7.95e-06	0.000244	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1R—breast cancer	7.93e-06	0.000243	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1R—breast cancer	7.9e-06	0.000242	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—CXCL8—breast cancer	7.89e-06	0.000242	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SMAD4—breast cancer	7.87e-06	0.000241	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—CXCL8—breast cancer	7.87e-06	0.000241	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1R—breast cancer	7.82e-06	0.00024	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—CXCL8—breast cancer	7.79e-06	0.000239	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HES1—breast cancer	7.79e-06	0.000239	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HES1—breast cancer	7.76e-06	0.000238	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NCOR1—breast cancer	7.74e-06	0.000237	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PLA2G4A—breast cancer	7.74e-06	0.000237	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PLA2G4A—breast cancer	7.72e-06	0.000237	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NCOR1—breast cancer	7.72e-06	0.000237	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HES1—breast cancer	7.69e-06	0.000236	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGF1—breast cancer	7.65e-06	0.000235	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CSF2—breast cancer	7.65e-06	0.000235	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NCOR1—breast cancer	7.64e-06	0.000234	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PLA2G4A—breast cancer	7.64e-06	0.000234	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—RAF1—breast cancer	7.64e-06	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGF1—breast cancer	7.63e-06	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CSF2—breast cancer	7.63e-06	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—RAF1—breast cancer	7.61e-06	0.000233	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NRG1—breast cancer	7.6e-06	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NRG1—breast cancer	7.57e-06	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CSF2—breast cancer	7.56e-06	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGF1—breast cancer	7.56e-06	0.000232	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—H2AFX—breast cancer	7.54e-06	0.000231	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—IL2—breast cancer	7.54e-06	0.000231	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—RAF1—breast cancer	7.54e-06	0.000231	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CAV1—breast cancer	7.52e-06	0.000231	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—H2AFX—breast cancer	7.52e-06	0.000231	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—IL2—breast cancer	7.52e-06	0.00023	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NRG1—breast cancer	7.5e-06	0.00023	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—E2F1—breast cancer	7.49e-06	0.00023	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—E2F1—breast cancer	7.47e-06	0.000229	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CB—breast cancer	7.46e-06	0.000229	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—H2AFX—breast cancer	7.45e-06	0.000228	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—IL2—breast cancer	7.44e-06	0.000228	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CB—breast cancer	7.43e-06	0.000228	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—E2F1—breast cancer	7.39e-06	0.000227	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CB—breast cancer	7.36e-06	0.000226	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SPP1—breast cancer	7.2e-06	0.000221	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SPP1—breast cancer	7.17e-06	0.00022	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—CXCL8—breast cancer	7.17e-06	0.00022	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—CXCL8—breast cancer	7.14e-06	0.000219	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ERBB3—breast cancer	7.12e-06	0.000218	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGFR2—breast cancer	7.11e-06	0.000218	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SPP1—breast cancer	7.1e-06	0.000218	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ERBB3—breast cancer	7.1e-06	0.000218	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGFR2—breast cancer	7.08e-06	0.000217	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—CXCL8—breast cancer	7.07e-06	0.000217	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ERBB3—breast cancer	7.03e-06	0.000215	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGFR2—breast cancer	7.02e-06	0.000215	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CG—breast cancer	6.85e-06	0.00021	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL2—breast cancer	6.85e-06	0.00021	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL2—breast cancer	6.83e-06	0.000209	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TERT—breast cancer	6.82e-06	0.000209	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TERT—breast cancer	6.8e-06	0.000208	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL2—breast cancer	6.76e-06	0.000207	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TERT—breast cancer	6.73e-06	0.000206	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGFR1—breast cancer	6.62e-06	0.000203	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGFR1—breast cancer	6.6e-06	0.000202	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGFR1—breast cancer	6.54e-06	0.0002	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HIF1A—breast cancer	6.52e-06	0.0002	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HIF1A—breast cancer	6.5e-06	0.000199	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HIF1A—breast cancer	6.44e-06	0.000197	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—LEP—breast cancer	6.37e-06	0.000195	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—LEP—breast cancer	6.35e-06	0.000195	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CAV1—breast cancer	6.31e-06	0.000193	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CAV1—breast cancer	6.29e-06	0.000193	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—LEP—breast cancer	6.29e-06	0.000193	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KDR—breast cancer	6.24e-06	0.000191	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CAV1—breast cancer	6.23e-06	0.000191	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KDR—breast cancer	6.22e-06	0.000191	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KDR—breast cancer	6.16e-06	0.000189	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ESR1—breast cancer	6.08e-06	0.000186	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ESR1—breast cancer	6.06e-06	0.000186	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CD—breast cancer	6.02e-06	0.000185	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FN1—breast cancer	6.01e-06	0.000184	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ESR1—breast cancer	6e-06	0.000184	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FN1—breast cancer	5.99e-06	0.000184	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ALB—breast cancer	5.95e-06	0.000182	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NFKBIA—breast cancer	5.94e-06	0.000182	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FN1—breast cancer	5.93e-06	0.000182	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NFKBIA—breast cancer	5.92e-06	0.000181	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOTCH1—breast cancer	5.88e-06	0.00018	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOTCH1—breast cancer	5.86e-06	0.00018	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NFKBIA—breast cancer	5.86e-06	0.00018	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOTCH1—breast cancer	5.8e-06	0.000178	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—APC—breast cancer	5.75e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KIT—breast cancer	5.75e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CG—breast cancer	5.75e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KIT—breast cancer	5.73e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CG—breast cancer	5.73e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—APC—breast cancer	5.73e-06	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—NOS3—breast cancer	5.69e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EGF—breast cancer	5.68e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CG—breast cancer	5.67e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KIT—breast cancer	5.67e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—APC—breast cancer	5.67e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EGF—breast cancer	5.66e-06	0.000174	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EGF—breast cancer	5.61e-06	0.000172	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—MAPK3—breast cancer	5.51e-06	0.000169	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—MAPK3—breast cancer	5.49e-06	0.000168	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—MAPK3—breast cancer	5.43e-06	0.000167	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—BRAF—breast cancer	5.4e-06	0.000166	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—BRAF—breast cancer	5.39e-06	0.000165	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—BRAF—breast cancer	5.33e-06	0.000163	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1—breast cancer	5.26e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT2—breast cancer	5.26e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CB—breast cancer	5.25e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1—breast cancer	5.25e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT2—breast cancer	5.24e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—EGFR—breast cancer	5.24e-06	0.000161	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—EGFR—breast cancer	5.22e-06	0.00016	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTGS2—breast cancer	5.2e-06	0.000159	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1—breast cancer	5.2e-06	0.000159	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT2—breast cancer	5.19e-06	0.000159	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—EGFR—breast cancer	5.17e-06	0.000158	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CD—breast cancer	5.05e-06	0.000155	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CD—breast cancer	5.04e-06	0.000154	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	5.01e-06	0.000153	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SERPINE1—breast cancer	5e-06	0.000153	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	4.99e-06	0.000153	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CD—breast cancer	4.99e-06	0.000153	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SERPINE1—breast cancer	4.98e-06	0.000153	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—KRAS—breast cancer	4.95e-06	0.000152	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	4.94e-06	0.000151	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SERPINE1—breast cancer	4.93e-06	0.000151	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—KRAS—breast cancer	4.93e-06	0.000151	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—KRAS—breast cancer	4.88e-06	0.00015	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOS3—breast cancer	4.77e-06	0.000146	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOS3—breast cancer	4.76e-06	0.000146	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOS3—breast cancer	4.71e-06	0.000144	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	4.55e-06	0.000139	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTEN—breast cancer	4.54e-06	0.000139	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	4.53e-06	0.000139	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MDM2—breast cancer	4.53e-06	0.000139	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MDM2—breast cancer	4.51e-06	0.000138	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—RAF1—breast cancer	4.51e-06	0.000138	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—RAF1—breast cancer	4.5e-06	0.000138	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—RELA—breast cancer	4.49e-06	0.000138	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	4.49e-06	0.000138	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—RELA—breast cancer	4.48e-06	0.000137	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MDM2—breast cancer	4.47e-06	0.000137	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ERBB2—breast cancer	4.46e-06	0.000137	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—RAF1—breast cancer	4.45e-06	0.000137	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ERBB2—breast cancer	4.45e-06	0.000136	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—RELA—breast cancer	4.43e-06	0.000136	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ERBB2—breast cancer	4.41e-06	0.000135	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CB—breast cancer	4.4e-06	0.000135	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MTOR—breast cancer	4.4e-06	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MTOR—breast cancer	4.39e-06	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CB—breast cancer	4.39e-06	0.000135	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CB—breast cancer	4.35e-06	0.000133	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MTOR—breast cancer	4.35e-06	0.000133	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CXCL8—breast cancer	4.23e-06	0.00013	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CXCL8—breast cancer	4.22e-06	0.000129	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—HRAS—breast cancer	4.21e-06	0.000129	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—HRAS—breast cancer	4.19e-06	0.000128	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CXCL8—breast cancer	4.18e-06	0.000128	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—HRAS—breast cancer	4.15e-06	0.000127	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1B—breast cancer	4.13e-06	0.000127	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1B—breast cancer	4.12e-06	0.000126	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AKT1—breast cancer	4.09e-06	0.000125	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1B—breast cancer	4.08e-06	0.000125	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AKT1—breast cancer	4.08e-06	0.000125	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CASP3—breast cancer	4.05e-06	0.000124	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL2—breast cancer	4.05e-06	0.000124	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CASP3—breast cancer	4.04e-06	0.000124	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AKT1—breast cancer	4.04e-06	0.000124	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL2—breast cancer	4.03e-06	0.000124	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL6—breast cancer	4.02e-06	0.000123	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL6—breast cancer	4.01e-06	0.000123	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CASP3—breast cancer	4e-06	0.000123	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL2—breast cancer	3.99e-06	0.000122	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL6—breast cancer	3.97e-06	0.000122	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCND1—breast cancer	3.94e-06	0.000121	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—JUN—breast cancer	3.94e-06	0.000121	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCND1—breast cancer	3.93e-06	0.00012	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—JUN—breast cancer	3.92e-06	0.00012	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CTNNB1—breast cancer	3.91e-06	0.00012	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CTNNB1—breast cancer	3.89e-06	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCND1—breast cancer	3.89e-06	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—JUN—breast cancer	3.88e-06	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CTNNB1—breast cancer	3.85e-06	0.000118	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MMP9—breast cancer	3.83e-06	0.000117	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MMP9—breast cancer	3.82e-06	0.000117	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1A—breast cancer	3.81e-06	0.000117	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PTEN—breast cancer	3.81e-06	0.000117	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1A—breast cancer	3.8e-06	0.000117	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PTEN—breast cancer	3.79e-06	0.000116	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MMP9—breast cancer	3.78e-06	0.000116	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1A—breast cancer	3.77e-06	0.000115	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PTEN—breast cancer	3.76e-06	0.000115	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAPK8—breast cancer	3.72e-06	0.000114	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AKT1—breast cancer	3.71e-06	0.000114	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAPK8—breast cancer	3.71e-06	0.000114	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AKT1—breast cancer	3.7e-06	0.000113	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAPK8—breast cancer	3.68e-06	0.000113	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AKT1—breast cancer	3.67e-06	0.000112	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SRC—breast cancer	3.53e-06	0.000108	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SRC—breast cancer	3.52e-06	0.000108	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SRC—breast cancer	3.48e-06	0.000107	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—VEGFA—breast cancer	3.44e-06	0.000105	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—VEGFA—breast cancer	3.43e-06	0.000105	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—STAT3—breast cancer	3.4e-06	0.000104	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—VEGFA—breast cancer	3.39e-06	0.000104	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—STAT3—breast cancer	3.39e-06	0.000104	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STAT3—breast cancer	3.36e-06	0.000103	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAPK3—breast cancer	3.25e-06	9.97e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAPK3—breast cancer	3.24e-06	9.94e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAPK3—breast cancer	3.21e-06	9.84e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CA—breast cancer	3.2e-06	9.81e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MYC—breast cancer	3.16e-06	9.7e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFB1—breast cancer	3.16e-06	9.67e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MYC—breast cancer	3.15e-06	9.66e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFB1—breast cancer	3.15e-06	9.64e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MYC—breast cancer	3.12e-06	9.57e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFB1—breast cancer	3.11e-06	9.55e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EGFR—breast cancer	3.09e-06	9.48e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EGFR—breast cancer	3.08e-06	9.45e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EGFR—breast cancer	3.05e-06	9.36e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KRAS—breast cancer	2.92e-06	8.96e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KRAS—breast cancer	2.91e-06	8.93e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KRAS—breast cancer	2.89e-06	8.84e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CA—breast cancer	2.69e-06	8.23e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CA—breast cancer	2.68e-06	8.2e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CA—breast cancer	2.65e-06	8.12e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—AKT1—breast cancer	2.61e-06	8.02e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TP53—breast cancer	2.6e-06	7.96e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TP53—breast cancer	2.59e-06	7.94e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TP53—breast cancer	2.56e-06	7.86e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HRAS—breast cancer	2.48e-06	7.61e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HRAS—breast cancer	2.48e-06	7.59e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HRAS—breast cancer	2.45e-06	7.52e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL6—breast cancer	2.38e-06	7.29e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL6—breast cancer	2.37e-06	7.26e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL6—breast cancer	2.35e-06	7.19e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT1—breast cancer	2.19e-06	6.72e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT1—breast cancer	2.19e-06	6.7e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT1—breast cancer	2.17e-06	6.64e-05	CbGpPWpGaD
